How has been the historical performance of Kashyap TeleMed.?
2025-11-17 23:23:15Answer: The historical performance of Kashyap TeleMed shows a relatively stable but low level of net sales over the years, with figures remaining at 0.19 Cr in both Mar'25 and Mar'24, and slightly higher at 0.20 Cr in Mar'23, Mar'22, and Mar'19. The total operating income has mirrored the net sales, remaining at 0.19 Cr in Mar'25 and Mar'24, while also being 0.20 Cr in the previous years. The company has not incurred any raw material costs, purchase of finished goods, or power costs during this period. Employee costs have increased from 0.05 Cr in Mar'17 to 0.11 Cr in Mar'25, indicating a gradual rise in operational expenses. However, total expenditure (excluding depreciation) peaked at 0.30 Cr in Mar'22 before decreasing to 0.19 Cr in Mar'25. Operating profit has fluctuated, with a loss of 0.03 Cr in Mar'24 and a break-even point in Mar'25, while profit before tax has remained at 0.00 Cr in Mar'25 and Mar'...
Read full news articleUn-Audited Financial Results (UFR) For The Third Quarter And Nine Months Ended December 31 2025 Along With The Statutory Auditors Limited Review Report
10-Feb-2026 | Source : BSEUn-Audited Financial Results for the Third Quarter and Nine Months ended December 31 2025 along with the Statutory Auditors Limited review report
Board Meeting Outcome for Un-Audited Financial Results (UFR) For The Third Quarter And Nine Months Ended December 31 2025 Along With The Statutory Auditors Limited Review Report
10-Feb-2026 | Source : BSEUn-Audited Financial Results (UFR) for the Third quarter and Nine months ended December 31 2025 along with the Statutory Auditors Limited Review Report
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
21-Jan-2026 | Source : BSEKashyap Tele-Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 inter alia to consider and approve Unaudited results for quarter ended December 31 2025
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






